Alimera Sciences (NASDAQ:ALIM) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a research note published on Wednesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, Alliance Global Partners downgraded shares of Alimera Sciences from a buy rating to a neutral rating and reduced their price target for the company from $11.00 to $4.50 in a research note on Monday, November 21st.

Alimera Sciences Stock Up 4.4 %

Shares of Alimera Sciences stock opened at $2.82 on Wednesday. The company has a market capitalization of $19.73 million, a price-to-earnings ratio of -1.07 and a beta of 1.31. Alimera Sciences has a 12-month low of $2.03 and a 12-month high of $7.92. The firm’s 50-day moving average price is $2.81 and its two-hundred day moving average price is $4.77.

Alimera Sciences (NASDAQ:ALIM – Get Rating) last announced its quarterly earnings data on Monday, November 14th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.38). The business had revenue of $13.60 million for the quarter, compared to analysts’ expectations of $15.60 million. On average, sell-side analysts expect that Alimera Sciences will post -2.33 earnings per share for the current year.

Institutional Investors Weigh In On Alimera Sciences

An institutional investor recently raised its position in Alimera Sciences stock. Renaissance Technologies LLC increased its holdings in shares of Alimera Sciences, Inc. (NASDAQ:ALIM – Get Rating) by 2.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 127,693 shares of the biopharmaceutical company’s stock after buying an additional 2,900 shares during the period. Renaissance Technologies LLC owned about 1.83% of Alimera Sciences worth $698,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 24.58% of the company’s stock.

Alimera Sciences Company Profile

(Get Rating)

Alimera Sciences, Inc engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion.